Innovative Medicine
Backed by the Power of AI
BioXcel Therapeutics, Inc. is a
biopharmaceutical company developing transformative medicines in neuroscience utilizing artificial intelligence.
Innovative Medicine
Backed by the
Power of AI
BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence, or AI, techniques.
Innovative Medicine
Backed by the Power of AI
BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence, or AI, techniques.
Our Approach to Drug Development
- Optimizes R&D economics
- Shortens development timelines
- Increases probability of success
AI-Driven Transformative Medicines in Neuroscience
We utilize our unique and proprietary AI platform to identify, re-innovate, and develop potential new therapies
Mar 25, 2024
BioXcel Therapeutics Announces $25 Million Registered Direct OfferingVIEW RELEASE
Mar 15, 2024
BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual DexmedetomidineVIEW RELEASE
Mar 12, 2024
BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023VIEW RELEASE
Stock Information
BioXcel Therapeutics, Inc.
Mar 28, 2024 11:46 AM
MARKET/SYMBOL
Nasdaq:
BTAI
PRICE
2.86
CHANGE
-0.02 (-0.69%)